The size of the Global Angina Pectoris Drugs Market is estimated to grow at a CAGR of 3.2% from 2020 to 2025.
Angina pectoris is a medical condition identified by precordial heaviness or distress due to temporary myocardial ischemia without infarction, elicited by physical or mental stress. Angina pectoris is classified as - stable, unstable, microvascular, and Prinzmetal. Angina pectoris is an initial symptom of coronary heart disease and significantly affects life quality, costs to society, and workability.
The increase in the number of ischemic heart diseases, rising geriatric population, and the adoption of a rich, westernized diet and subsequent growth of smoking, obesity, and diabetes are significantly driving the development of the global angina pectoris drugs market. Several new investigational drugs are being tested to treat chronic angina and reduce currently marketed drugs' side effects. The increased prevalence of cardiovascular diseases and the rise in the geriatric population are driving the market growth. Growing research and development projects in the healthcare segment and augmented healthcare expenditure further expand the angina pectoris drugs market.
Currently, only a few research activities are being conducted specifically to treat angina pectoris. Not many approvals have been granted for the novel compounds in the past few years, limiting the market growth. A majority of patients with chest pain remain undiagnosed with the possibility of suffering from angina or buying generic medicines instead of specific branded medicines, which hampers the demand in the global Angina Pectoris drugs market. Along with this, non-adherence to cardiovascular medications has also been observed among patients suffering from cardiovascular diseases, which may further hinder the market growth.
Impact of COVID-19 on Angina Pectoris Drugs Market
The Covid-19 pandemic has impacted society and the overall economy across the world and caused uncertainty in the stock market, massive disruption of the supply chain, falling business confidence, and increasing panic among the customer segments. As the different regions' governments have already announced a complete lockdown and temporary closedown of industries, the overall production process is adversely affected, thus hindering the overall angina pectoris drugs globally.
Market Size Available
2019 to 2025
2020 to 2025
By Therapeutic Class and Region
Various Analyses Covered
Global, Regional & Country Level Analysis, Segment-Level Analysis, DROC, PESTLE Analysis, Porter’s Five Forces Analysis, Competitive Landscape, Analyst Overview on Investment Opportunities
North America, Europe, Asia Pacific, Latin America, Middle East & Africa
This research report on the global angina pectoris drugs market has been segmented and sub-segmented based on the therapeutic class and region.
Angina Pectoris Drugs Market – By Therapeutic Class:
Beta-blockers work by blocking the hormone epinephrine (adrenaline) effects, which causes the heart to beat more slowly and with less force, thus easing the blood pressure. Combining nitrates with beta-blockers is most used to block tachycardia and generating a synergetic anti-ischaemic effect. The Beta-Blocker market now is predominately generic with key patent expirations impacting GlaxoSmithKline's Coreg and AstraZeneca's Toprol. Post Pfizer's Norvasc patent being determined invalid in 2007, the Calcium Antagonist market is predominantly generic.
A few of the emerging anti-anginal drugs are nicorandil, ivabradine, ranolazine, and trimetazidine.
Angina Pectoris Drugs Market – By Region:
Geographically, the global angina pectoris drugs market was dominated by North America in 2019, with the overall market share of over 33% globally. Europe and Asia-Pacific followed North America. North America controls the Angina Pectoris Drugs market is driven by the organized healthcare infrastructure, increased adoption of therapeutics, and key manufacturers in the U.S. responsible for its large share. Ischaemic heart disease is among the significant cause of death and disability worldwide, while angina represents its most common symptom. It is estimated that approximately 9 million patients in the USA suffer from angina and its treatment is challenging. Moreover, the increasing incidence of cardiac disorders due to the sedentary lifestyle and favorable regulatory initiatives fuel market growth. Approximately 9.8 million Americans are estimated to experience angina annually, with 500,000 new angina cases occurring every year.
The European market follows North America with EU5 leading the market share due to developed medical care facilities and a good reimbursement scenario.
The Asia Pacific is predicted to grow at a rapid pace in the coming few years. Asia Pacific region represents a vast market opportunity for the anti-angina drug market owing to the increasing number of cardiovascular problems and improvising healthcare facilities.
The Middle East and Africa represent the least market share, but a vast market opportunity has been anticipated with the increasing burden of ischemic heart diseases in these regions. Furthermore, Ischemic heart disease is the leading cause of death globally. The vast majority of it occurs outside the high-income world, increasing market opportunities in low- and middle-income countries.
NOTABLE COMPANIES IN THE MARKET
Some of the key competitors leading the Global Angina Pectoris Drugs Market profiled in this report are Sanofi, Bayer HealthCare, Cardeus Pharmaceuticals and CardioVascular BioTherapeutics (CVBT), Merck & Co. Inc., Anthera Pharmaceuticals, Cardium Therapeutics, Astellas Pharma, Ark Therapeutics Group plc, Torrent Pharmaceuticals Limited, Circ Pharma Limited, HUYA Bioscience International LLC, Lacer S.A., Viromed Co. Ltd., and Baxter Healthcare Corporation.
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3.1 Executive Summary
3.2 Key Inferences
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Therapeutic class
5.1.2 Beta blockers
5.1.3 Calcium anatagonists
5.1.5 Anti platelets
5.1.7 Y-o-Y Growth Analysis, By therapeutic class
5.1.8 Market Attractiveness Analysis, By therapeutic class
5.1.9 Market Share Analysis, By therapeutic class
6. Geographical Analysis
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
220.127.116.11 By Geographical Area
18.104.22.168 By therapeutic class
6.1.4 Market Attractiveness Analysis
22.214.171.124 By Geographical Area
126.96.36.199 By therapeutic class
6.1.5 Market Share Analysis
188.8.131.52 By Geographical Area
184.108.40.206 By therapeutic class
6.2 North America
6.1.2 United States
6.3.6 South Korea
6.5 Latin America
6.4.5 Rest of Latin America
6.6 Middle East & Africa
7. Strategic Analysis
7.1 PESTLE analysis
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8. Market Leaders' Analysis
8.1 Anthera Pharmaceuticals
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 Cardium Therapeutics
8.4 Bayer HealthCare
8.5 Cardeus Pharmaceuticals
8.6 Ark Therapeutics Group plc
8.7 Torrent Pharmaceuticals Limited
8.8 Circ Pharma Limited
8.9 Viromed Co. Ltd.
9. Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10. Market Outlook and Investment Opportunities
a) List of Tables
b) List of Figures